Brief: Immunocore Announces That U.S. FDA And EMA Accept Biologics License Application And Marketing Authorization Application For Tebentafusp In Metastatic Uveal Melanoma

Immunocore Holdings

24/08/2021 15:23

Aug 24 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE ANNOUNCES THAT U.S. FOOD AND DRUG
ADMINISTRATION AND
EUROPEAN MEDICINES AGENCY ACCEPT BIOLOGICS LICENSE APPLICATION
AND MARKETING AUTHORIZATION APPLICATION FOR TEBENTAFUSP IN
METASTATIC UVEAL MELANOMA
    * IMMUNOCORE HOLDINGS PLC - FDA GRANTS PRIORITY REVIEW TO
TEBENTAFUSP FOR TREATMENT OF HLA-A*02:01-POSITIVE PATIENTS WITH
METASTATIC UVEAL MELANOMA
    * IMMUNOCORE HOLDINGS PLC -  FOR TEBENTAFUSP, EXPECTED
PRESCRIPTION DRUG USER FEE ACT TARGET ACTION DATE OF FEB 23,
2022
    * IMMUNOCORE - EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR
HUMAN USE
WILL REVIEW TEBENTAFUSP APPLICATION  UNDER ACCELERATED
ASSESSMENT PROCEDURE

Source text for Eikon:  ID:nGNX7YHGnP 
Further company coverage:  IMCR.O 

 ((reuters.briefs@thomsonreuters.com;))